$80.39
-0.45-0.56%
At Close: -
$80.39
00.00%
After Hours: Jul 26, 4:46 PM EDT
15 minutes delayed
Intra-Cellular Therapies reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Intra-Cellular Therapies using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ITCI | Intra-Cellular Therapies | -$0.45 | -$0.18 | — | — | $110.79M | $158.34M | — | — | 08/07/2024 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.46 | -$0.33 | -$0.16 | 51.52% | $95.31M | $140.91M | $144.87M | 2.81% | 05/07/2024 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.45 | -$0.43 | -$0.30 | 30.23% | $87.87M | $136.79M | $132.10M | -3.43% | 02/22/2024 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.57 | -$0.56 | -$0.25 | 55.36% | $71.87M | $119.35M | $126.17M | 5.72% | 11/02/2023 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.92 | -$0.62 | -$0.45 | 27.42% | $55.58M | $106.56M | $110.79M | 3.97% | 08/03/2023 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.78 | -$0.60 | -$0.46 | 23.33% | $35.00M | $91.98M | $95.31M | 3.62% | 05/04/2023 | Get Alert |
ITCI | Intra-Cellular Therapies | -$1.05 | -$0.59 | -$0.45 | 23.73% | $25.67M | $86.97M | $87.87M | 1.03% | 03/01/2023 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.95 | -$0.81 | -$0.57 | 29.63% | $22.21M | $66.00M | $71.87M | 8.89% | 11/03/2022 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.85 | -$0.76 | -$0.92 | -21.05% | $20.05M | $49.02M | $55.58M | 13.38% | 08/09/2022 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.65 | -$0.92 | -$0.78 | 15.22% | $15.88M | $33.65M | $35.00M | 4.00% | 05/10/2022 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.76 | -$1.00 | -$1.05 | -5.00% | $12.45M | $25.37M | $25.67M | 1.19% | 03/01/2022 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.79 | -$0.92 | -$0.95 | -3.26% | $7.37M | $22.12M | $22.21M | 0.39% | 11/09/2021 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.96 | -$0.80 | -$0.85 | -6.25% | $1.91M | $19.44M | $20.05M | 3.12% | 08/09/2021 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.73 | -$0.80 | -$0.65 | 18.75% | $1.08M | $16.50M | $15.88M | -3.77% | 05/10/2021 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.74 | -$0.85 | -$0.76 | 10.59% | $60.61K | $11.84M | $12.45M | 5.19% | 02/25/2021 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.63 | -$1.00 | -$0.79 | 21.00% | $0.00 | $5.86M | $7.37M | 25.75% | 11/09/2020 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.68 | -$0.91 | -$0.96 | -5.49% | $0.00 | $3.03M | $1.91M | -37.06% | 08/10/2020 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.63 | -$0.93 | -$0.73 | 21.51% | $0.00 | $1.44M | $1.08M | -24.79% | 05/07/2020 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.75 | -$0.81 | -$0.74 | 8.64% | $0.00 | — | $60.61K | — | 03/02/2020 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.76 | — | -$0.63 | — | $0.00 | — | $0.00 | — | 11/05/2019 | Get Alert |
ITCI | Intra-Cellular Therapies | -$0.68 | -$0.83 | -$0.68 | 18.07% | $0.00 | $10.00K | $0.00 | -100.00% | 08/07/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $-0.16 | $-0.33 | 51.5 % |
Dec 2023 | 2024-02-22 | $-0.30 | $-0.43 | 30.2 % |
Sep 2023 | 2023-11-02 | $-0.25 | $-0.56 | 55.4 % |
Jun 2023 | 2023-08-03 | $-0.45 | $-0.62 | 27.4 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $144.87M | $140.91M | 2.81 % |
Dec 2023 | 2024-02-22 | $132.10M | $136.79M | -3.43 % |
Sep 2023 | 2023-11-02 | $126.17M | $119.35M | 5.72 % |
Jun 2023 | 2023-08-03 | $110.79M | $106.56M | 3.97 % |
Intra-Cellular Therapies (ITCI) is scheduled to report earnings on August 7, 2024. The last reported earnings were for reported on May 7, 2024 for Q1.
The Actual EPS was $-0.16, which beat the estimate of $-0.33.
The Actual Revenue was $144.9M, which beat the estimate of $140.9M.
Browse earnings estimates, EPS, and revenue on all stocks.